Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

Описание к видео Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Website: https://www.onclive.com
Twitter:   / onclive  
Facebook:   / onclive  
LinkedIn:   / onclive  

Комментарии

Информация по комментариям в разработке